Furthermore, the clinical viability of JAK2 PROTACs is yet to be determined and, in the absence of PROTAC ligands specific for mutant-JAK2 or JAK2 fusions, JAK2 PROTACS may induce anemia and thrombocytopenia due to degradation of WT JAK2, therefore, further investigations are required. This evidence concerns the gene JAK2 and anemia.